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EfﬁcacyIn an ongoing open-label extension (OV-1004), patients with Lennox–Gastaut syndrome who had completed
1 of 2 randomized controlled trials (OV-1002 [Phase II] or OV-1012 [Phase III]) are receiving clobazam at
dosages ≤2.0 mg/kg/day (≤80 mg/day). Of 306 eligible patients from OV-1002 or OV-1012, 267 entered
the open-label extension. As of the interim date, July 1, 2010, 213 patients (79.8%) had remained in the
trial, and 189 had received clobazam for ≥12 months, 128 for ≥18 months, and 94 for ≥24 months. Median
percentage decreases in average weekly rates of drop seizures were 71.1% and 91.6% at Months 3 and 24.
Mean modal and mean maximum daily dosages were 0.94 mg/kg and 1.22 mg/kg for those who had received
clobazam for≥1 year. The 4 most common adverse events were upper respiratory tract infection (18.4%), fall
(14.2%), pneumonia (13.9%), and somnolence (12.7%). Clobazam's adverse event proﬁle was consistent with
its proﬁle in controlled trials.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Lennox–Gastaut syndrome (LGS) is a severe form of chronic epi-
leptic encephalopathy that usually manifests in early childhood,
with peak age of onset between 3 and 5 years [1]. The most common
seizure types associated with LGS are tonic and atonic seizures, also
known as “drop attacks,” which occur in at least 50% of patients
with LGS. Drop attacks are often the ﬁrst seizure type to manifest in
LGS and have the most potential for bodily harm [2,3]. As a chronic
syndrome, LGS requires lifelong treatment, and patients almost
always develop progressive behavioral and psychological deﬁcits
[1,3]. The treatment goal for most seizure disorders is complete sei-
zure remission. However, remission is rarely achieved in LGS. Instead,
the treatment goal for LGS is to improve individual patient quality of
life through a decrease in seizure frequency with the fewest adverseUniversity of Oklahoma Health
klahoma City, OK 73104, USA.
-NC-ND license.events [4,5]. The several seizure types experienced by patients with
LGS (i.e., tonic, clonic, atypical absence, atonic, myoclonic, partial
[focal], generalized tonic-clonic, and nonconvulsive status epilepticus
seizures) and their resistant nature often result in years of poly-
therapy [1,4,5]. The chronic, progressive, and complex nature of this
syndrome makes LGS inherently difﬁcult to treat, and a paucity of
quality long-term trial data has also been an impediment to optimiz-
ing treatment for these patients [1,4,5].
Clobazam is a novel 1,5-benzodiazepine approved by the US Food
and Drug Administration (FDA) in October 2011 for the treatment of
seizures associated with LGS. Clobazam, ﬁrst approved in Australia in
1970 and in France in 1974 [6], is also approved for the treatment of
anxiety and many forms of epilepsy outside the United States. The US
Food and Drug Administration's approval of clobazam for LGS was
based on 2 randomized controlled trials, OV-1002 [7] and OV-1012
(also known as the CONTAIN trial) [8]. The OV-1002 study was a
Phase II trial of patients with LGS 2–30 years of age, from which
clobazam was found to be well-tolerated and to have decreased the
weekly frequency of drop and non-drop seizures. Two clobazam dos-
ages were studied (1.0 mg/kg/day and 0.25 mg/kg/day): Both dosages
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efﬁcacious than the 0.25 mg/kg/day dosage. OV-1012 (the CONTAIN
study) was a Phase III placebo-controlled trial evaluating 3 clobazam
dosages in adult and pediatric patients 2–60 years of age. In this
study, treatment with clobazam 0.25, 0.5, or 1.0 mg/kg/day was
well-tolerated and efﬁcacious in the treatment of drop seizures for
patients with LGS. Compared with placebo, clobazam signiﬁcantly de-
creased average weekly rates of drop seizures (12.1%, 41.2%, 49.4%,
and 68.3% for the placebo, 0.25, 0.5, and 1.0 mg/kg/day dosages, respec-
tively) and total seizures (9.3%, 34.8%, 45.3%, and 65.3% for the placebo,
0.25, 0.5, and 1.0 mg/kg/day dosages, respectively) [8].
After participation in studies OV-1002 or OV-1012, patients
were eligible to enroll in a long-term, open-label extension trial,
OV-1004. An interim data analysis of this ongoing trial was con-
ducted, covering the period from December 28, 2005, through July
1, 2010, and these data were used in the FDA's review of clobazam
for approval. Safety and efﬁcacy data from this interim analysis are
presented here.
2. Methods
2.1. Study design
Qualifying patients from 2 randomized controlled studies (OV-1002
[7] and OV-1012 [8]) were given the option of continuing clobazam
treatment in OV-1004, an ongoing, multicenter, open-label study of
clobazam as adjunctive therapy in patients with LGS 2–60 years of
age. Patients who met the following criteria were eligible to enroll in
OV-1004: b14 days since last dose of study drug in previous study, no
serious or adverse events probably or deﬁnitely related to clobazam
(as deemed by investigators), and receipt of ≤3 concomitant anti-
epileptic drugs (AEDs). Only in OV-1002 were vagus nerve stimulation
(VNS) and ketogenic diet recorded as an AEDwhen patients enrolled inFig. 1. Controlled and open-label study designs. aEnd of previous blinded Lundbeck-sponsor
who participated in OV-1012 (patients in OV-1002 had passed the Week-1 time point priothe study. To account for this difference in methodology between
OV-1002 and OV-1012, treatment baselines were adjusted for all
OV-1012 patients so that the numbers of concomitant AEDswere calcu-
lated in the same manner as for OV-1002 patients. This is particularly
important for the analysis reported in Section 3.3.2.4 covering changes
over time in concomitant epilepsy treatments.
Receipt of >3 concurrent AEDs was permitted after enrolment in
OV-1004. The study designs for all 3 trials are provided in Fig. 1.
When all required procedures from the previous blinded study
were completed, patients were considered closed out of the previous
blinded study and formally entered into the open-label study. The
Day-1 procedures were performed, and open-label clobazamwas dis-
pensed to patients and/or their parents/caregivers. During the Day-1
visit, the patient or the patient's legally authorized representative
signed and dated the Institutional Review Board (IRB)/Independent
Ethics Committee (IEC)–approved informed consent form/Health
Insurance Portability and Accountability Act (HIPAA) authorization
form and assent, if appropriate.
Patients who were undecided about continuing in the open-label
study upon completion of the treatment period or premature discontin-
uation from OV-1002 or OV-1012 were considered eligible for enroll-
ment for 14 days following their ﬁnal doses of study drug. Patients
who had decided to continue in the open-label study during this
14-day window returned to the investigational site for the Day-1 visit.
If the investigator determined that there had been a signiﬁcant change
in a patient's medical history since the end of the previous blinded
study, a complete physical examination and full neurologic examination
were performed at the visit at Day 1 (versus using the information col-
lected during the last visit of the previous blinded study).
During the open-label treatment period, patients returned to the
investigational site at Week 1 (OV-1012 patients only) and Months
1, 2, 3, 6, 9, and 12, and then every 6 months thereafter. For patients
outside the United States, the treatment period was limited toed study and the start of the open-label study. b“Week-1 visit” only applied to patients
r to the amendment change that added Week- 1 procedures).
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the trial until clobazam was commercially available. During the
week preceding each study visit, the parent/caregiver, with the assis-
tance of the patient, if able, maintained a seizure diary in which daily
seizure counts (including drop seizures) were recorded.
Patients who prematurely discontinued treatment or completed
the study and did not continue on commercially available clobazam
entered the 3-week taper period. The patients had a phone visit
2 weeks after entering the taper period and an ofﬁce visit 1 week
after the last dose of study drug.
2.2. Clobazam and concomitant AED dosing
Clobazam was given twice daily, in the morning and at bedtime.
Patients from OV-1012 started at a target dosage of 0.5 mg/kg/day
(maximum: 40 mg/day). This dosage was maintained for 48 h and
then adjusted per clinical need. The unblinded physician adjusted or
maintained the clobazam dosages the patients received in OV-1002
when they entered OV-1004. The maximum allowed daily dosage for
all patients in OV-1004 was 2.0 mg/kg/day (maximum: 80 mg/day).
While target dosages did not exceed 1.0 mg/kg/day (maximum:
40 mg/day) in the randomized Phase II and III clobazam studies [7,8],
a target dosage of 2.0 mg/kg/day (80 mg/day) was allowed in the
open-label extension study based on published reports of dosages
>1 mg/kg/day (≤3.8 mg/kg/day, maximum 130 mg/day) being used
in other refractory seizure disorders [9].
To optimize patient care, investigators were able to start, adjust,
and discontinue other AEDs and initiate other forms of treatment, in-
cluding ketogenic diets and VNS placement.
2.3. Efﬁcacy assessments
2.3.1. Primary efﬁcacy population and measure
The efﬁcacy population included all patients who received ≥1
dose of clobazam and had ≥1 efﬁcacy measurement during the
open-label study. Day 1 refers to the day the ﬁrst dose of clobazam
was received. The ﬁrst dose of clobazam was received in OV-1002
and OV-1012 (clobazam-treated patients) or in OV-1004 (placebo-
treated patients from OV-1012 who started open-label clobazam).
The primary efﬁcacy outcome was the percentage decrease in the av-
erage weekly rate of drop seizures at various time intervals compared
with baseline values (deﬁned as the last 7 non-missing seizure
entries; see “Statistical analyses,” Section 2.5, for more details). The
percentage decrease in the average weekly rate of total seizures was
also measured. Drop seizures were recorded by patients' parents/
caregivers in daily seizure diaries. Drop seizure was deﬁned as a
drop attack or spell involving the entire body, trunk, or head that
led to a fall, injury, slumping in a chair, or the patient's head hitting
a surface, or that could have led to a fall or injury, depending on the
patient's position at the time of the attack or spell. Drop seizures
were recorded as a single seizure (occurring 15 min before and after
the next seizure) or cluster of seizures (2 drop seizures with 5 min
between any 2 consecutive seizures). For clusters, an exact number
of drop seizures or a seizure range (10–20 drop seizures or >20 drop
seizures) could have been recorded [8].
2.3.2. Additional efﬁcacy measures
Additional efﬁcacy outcomes included time to discontinuation of
clobazam, percentage of treatment responders, global evaluations of
patients' overall changes in symptoms, and changes in concomi-
tant AED use. Treatment responders were deﬁned as patients with
≥25%, ≥50%, ≥75%, and 100% decreases in drop seizures or total
seizures from the previous study baseline period. Investigator and
parent/caregiver global evaluations of patients' overall changes in
symptom assessments were based on a 7-point scale from 1 (verymuch improved) to 7 (very much worse), with lesser scores indicat-
ing improvement in overall evaluation of symptoms.
2.4. Safety assessments
The primary overall objective of the OV-1004 open-label trial was
collection of safety information. The safety population included all pa-
tients who received ≥1 dose of clobazam during this trial. Measures
included laboratory assessments (chemistry, hematology, and urinal-
ysis), physical and neurologic examinations, vital sign monitoring,
electrocardiogram monitoring, and adverse event reporting.
A serious adverse event was deﬁned as any adverse event, which oc-
curred at any dosage, that 1) resulted in death, 2) was life-threatening,
3) resulted in inpatient hospitalization or prolongation of existing
hospitalization, 4) led to persistent or signiﬁcant disability/incapacity,
5) yielded a congenital anomaly/birth defect, or 6) was an important
medical event that, based on appropriate medical judgment, may have
jeopardized a patient or required surgery or medical intervention to
prevent the above outcomes. For an adverse event to be serious, it
must have met one of these 5 predeﬁned criteria. A severe adverse
event was deﬁned as any adverse event that may have interfered with
the patient's usual activities and may have been incapacitating or
life-threatening. Adverse events were deemed severe at the sole discre-
tion of the individual study investigators.
2.5. Statistical analyses
The Safety Analysis Set consists of all patients who received ≥1
dose of clobazam in OV-1004. The Efﬁcacy Analysis Set consists of
all patients who received ≥1 dose of clobazam and had ≥1 efﬁcacy
measurement during the study. Selected variables are summarized
for patients based on the timing of ﬁrst dose compared with the
date of the data cutoff in the trial. For example, a 6-month subset of
patients received clobazam for at least 6 months but less than
12 months before data cutoff.
Demographic data for all patients were re-collected upon entry
into OV-1004. Neurologic history data were only collected at screen-
ing in the previous blinded studies. Baseline values for seizure analy-
ses were calculated as follows: (1) for patients who received placebo
in OV-1012, baseline corresponded to the last 7 non-missing diary
days; or (2) for patients who received clobazam in OV-1002 or
OV-1012, baseline corresponded to the last 7 non-missing diary
days from the baseline period of the blinded study. For all other pa-
rameters (e.g., exposure, laboratory evaluations, and vital signs),
baseline was deﬁned as the last value obtained before the ﬁrst dose
of clobazam, whether in the previous blinded study or OV-1004.
2.5.1. Efﬁcacy analyses
This report includes all interim data as of July 1, 2010. All data are
observed values and were summarized by study visit with descriptive
statistics. Numbers and percentages were used for categorical vari-
ables, whereas mean, standard deviation (SD), median, minimum,
and maximum values were used for continuous or ordinal measures.
Calculation of values for clobazam treatment ≥1 day began on the
day patients received their ﬁrst doses of clobazam. For all clobazam-
treated patients, the ﬁrst dose of clobazam was received in OV-1002
and OV-1012, whereas placebo-treated patients from OV-1012 re-
ceived their ﬁrst doses of clobazam in OV-1004.
2.5.2. Safety analyses
For each patient, themost common (modal) andmaximum dosages
of clobazam were calculated. Descriptive summaries of the mean mod-
al and mean maximum dosages were provided for patients who re-
ceived clobazam for ≥1 day (any clobazam exposure), ≥6 months,
and≥12 months. In addition, the numbers and percentages of patients
were cross-tabulated by modal dosage and days of clobazam exposure.
Fig. 2. Patient ﬂow through the study. CLB, clobazam; PBO, placebo.
Fig. 3. Time to discontinuation of clobazam. Day 1 is the ﬁrst day of clobazam dosing,
regardless if it occurred in the blinded study or OV-1004.
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severity (mild, moderate, or severe), relationship to treatment (not
related, possible, or probable), and seriousness.
3. Results
3.1. Patient disposition
Enrollment in this open-label study began in December 2005 and
ended in December 2009. This interim analysis reports data from the
ﬁrst patient enrolled to the most recent data cutoff, July 1, 2010.
A total of 267 patients enrolled in the open-label study and were
included in the efﬁcacy and safety populations for OV-1004 (Fig. 2).
As of the cutoff date for this interim analysis, 20% of patients had
discontinued participation in the trial (Fig. 2). The most common rea-
son for discontinuation was patient, parent, or caregiver request
(7.9%). Other reasons (b5%) included lack of efﬁcacy, adverse events,
and death. Treatment-emergent adverse events that led to premature
discontinuation of clobazamwere reported for 13 patients (4.9%). The
only adverse events that led to premature discontinuation for >1 pa-
tient were pneumonia (3 patients) and death of unknown origin or
etiology (2 patients). Time to discontinuation of clobazam ranged
from 17 to 1317 days and is displayed graphically using Kaplan–
Meier estimates in Fig. 3.
3.2. Patient demographics
Demographics and baseline data from Day 1 in OV-1004 are
presented in Table 1. Mean age at the beginning of the trial was
11 years, with a mean time since LGS diagnosis of 4.3 years. All pa-
tients enrolled in the open-label extension trial were receiving con-
comitant AEDs at study entry. The most common concomitant AEDs
received by patients at baseline were valproic acid (52%), lamotrigine
(36%), levetiracetam (36%), and topiramate (30%). All concomitant
AEDs received by >10% of patients are presented in Table 1.3.3. Efﬁcacy results
3.3.1. Primary efﬁcacy outcome
The median percentage decreases from baseline in average weekly
rate of drop seizures for total patients, regardless of duration of
clobazam treatment, were 71.1% at Month 3 and 91.6% at Month 24
(Fig. 4). Median percentage decreases in total seizures in this popula-
tion were 64.8% at Month 3 and 81.5% at Month 24 (Fig. 4).
3.3.2. Additional outcomes
3.3.2.1. Treatment responders. The percentage of patients with a ≥25%,
≥50%, ≥75%, or 100% decrease in average weekly seizure rate from
previous blinded study baseline increased from Month 3 to Month
Table 1
Patient baseline demographics and disease characteristics.a
Characteristic N=267
Age, years
Mean (SD) 11.1 (7.8)
Median (range) 9.0 (2–54)
Male, n (%) 163 (61.0)
Race, n (%)
White 176 (65.9)
Asian 53 (19.9)
Black 31 (11.6)
Other 7 (2.6)
Ethnicity, n (%)
Hispanic/Latino 32 (12.0)
Non-Hispanic/Latino 235 (88.0)
Time since LGS diagnosis, years
Mean (SD) 4.3 (5.8)
Median (range) 2.1 (0–51)
Most common concomitant AEDs,b n (%)
Valproic acid 140 (52.4)
Lamotrigine 97 (36.3)
Levetiracetam 96 (36.0)
Topiramate 80 (30.0)
Diazepam 56 (21.0)
Zonisamide 45 (16.9)
Felbamate 44 (16.5)
Ruﬁnamide 37 (13.9)
Lorazepam 27 (10.1)
Phenobarbital 27 (10.1)
AEDs = antiepileptic drugs.
a Data from Day 1 of OV-1004 open-label extension trial; for the majority of
patients, Day 1 was not the ﬁrst day they received clobazam.
b Received by ≥10% of patients at baseline.
Fig. 5. Percentage of patients with 25%, 50%, 75%, or 100% decrease in weekly rate of
drop (A) and total (B) seizures from baseline. A. Drop seizures. B. Total seizures.
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of patients with a ≥50% drop seizure response rate were 61.5% at
Month 3 (n=252) and 79.5% at Month 24 (n=88). The percentages
of patients with a ≥50% total seizure response rate were 61.5% at
Month 3 (n=260) and 70.3% at Month 24 (n=91).
3.3.2.2. Efﬁcacy sustainment. To determine if clobazam maintained a
therapeutic effect in initial responders, we analyzed the percentages
of patients over time who had ≥50%, ≥75%, or 100% decreases in av-
erage weekly rates of drop seizures for the subpopulation of patients
who had attained ≥50% reduction at Month 3. Response to clobazam
remained fairly consistent for those patients with initial responses, as
measured by reduction in average weekly drop seizure rate (Table 2).
3.3.2.3. Physician and patient caregiver global evaluations. The majority
of patients were assessed by the physician as “very much improved”
or “much improved” at all time points (range: 66.3–82.3%), and thisFig. 4. Percentage decrease in weekly rate of drop and total seizures from baseline pe-
riod in previous study. Total number of patients (n) is given in the bottom of each bar.percentage increased from Month 3 to Month 24 (data not shown).
Similarly, the majority of patients were “very much improved” or
“much improved” at all time points when assessed by the parent/
caregiver (range: 61.5–80.5%), and this percentage also increased
from Month 3 to Month 24 (data not shown).
3.3.2.4. Concomitant epilepsy treatments. Because of protocol devia-
tions, differences in baseline inclusion criteria between the Phase II
and III studies, and other reasons, 23 patients were receiving >3
concomitant epilepsy treatments at entry into OV-1004. Of these 23
patients who were receiving >3 concomitant epilepsy treatments
(AEDs, ketogenic diet, and/or VNS) at baseline, 10 (43.5%) wereTable 2
Ongoing drop seizure responder rates in subset of patients with initial response (≥50%
decrease in drop seizures at Month 3).
Month 6 Month 9 Month 12 Month 18 Month 24
Patients, n 143 131 112 83 60
≥50% reduction, % 87.4 84.7 89.3 79.5 88.3
≥75% reduction, % 67.8 70.2 75.0 63.9 85.0
100% reduction, % 41.3 39.7 45.5 37.3 48.3
Table 4
Modal and maximum dosages of clobazam.
Dosage,
mg/kg/day
Clobazam exposure
≥1 day
(n=267)
≥6 months
(n=251)
≥12 months
(n=189)
Modal
Mean (SD) 0.88 (0.50) 0.90 (0.51) 0.94 (0.51)
Median 0.77 0.78 0.82
Q1, Q3 0.48, 1.16 0.50, 1.24 0.53, 1.29
Maximum
Mean (SD) 1.13 (0.57) 1.16 (0.57) 1.22 (0.58)
Median 1.00 1.00 1.04
Q1, Q3 0.66, 1.43 0.78, 1.46 0.91, 1.52
Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation.
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patients who were receiving 3 concomitant epilepsy treatments at
baseline, 36 (46.2%) were receiving fewer treatments at their ﬁnal
evaluations. In contrast, the majority of patients who were receiving
1 or 2 concomitant epilepsy treatments at baseline (n=128)
remained on the same number of treatments at their ﬁnal evaluations
(19/24 [79.2%] and 73/104 [70.2%], respectively). At ﬁnal evaluation,
the number of concomitant epilepsy treatments increased for 5 of
24 patients (20.8%) who were receiving 1 concomitant epilepsy treat-
ment at baseline. For the 104 patients receiving 2 concomitant epilep-
sy treatments at baseline, the number of concomitant epilepsy
treatments increased for 14 (13.5%) patients and decreased for 17
(16.3%). A cross-tabulation of numbers of concomitant AEDs at baseline
and ﬁnal evaluation is provided in Table 3.
3.4. Safety results
3.4.1. Extent of exposure
The mean modal and mean maximum dosages of clobazam were
similar for patients with ≥1 day, ≥6 months, and ≥12 months of
clobazam exposure (Table 4). The distribution of modal dosages did
not change markedly for the group of patients who reached longer
exposures to clobazam (≥24 months) compared with those who
were in the study for short durations (data not shown). As of July 1,
2010, one patient received greater than the maximum per protocol
dosage of clobazam (80 mg/day). This patient received a total
clobazam dosage of 100 mg/day from October 26, 2009, to November
04, 2009. The weight of this patient during this period was 20.8 kg.
3.4.2. Adverse events
3.4.2.1. Incidence of adverse events. A total of 219 (82.0%) patients
experienced ≥1 treatment-emergent adverse event during the open-
label study, and 140 (52.4%) patients experienced ≥1 adverse event
thatwas treatment-related (deﬁned as possible, probable, or deﬁnite re-
lationship to study drug as assessed by the investigator). Themost com-
mon treatment-emergent adverse events (≥10% of patients) in this
extension study, in order of descending incidence,were upper respirato-
ry tract infection (49/267, 18.4%), fall (38/267, 14.2%), pneumonia (37/
267, 13.9%), somnolence (34/267, 12.7%), otitis media (32/267, 12.0%),
pyrexia (28/267, 10.5%), and constipation (27/267, 10.1%). Theupper re-
spiratory tract infection and pneumonia events occurred predominantly
in pediatric patients (80–90% in patients under the age of 18).
Of adverse events with an incidence ≥10% in OV-1004, the inci-
dence and prevalence generally decreased after the ﬁrst 6 months
of treatment for the following: upper respiratory tract infection, som-
nolence, otitis media, and pyrexia.
3.4.2.2. Severity of adverse events. Mild or moderate adverse events
were reported for 160 patients (59.9%), and severe adverse events
were reported for 59 patients (22.1%). Severe treatment-emergent ad-
verse events reported for ≥1.0% of patients were pneumonia and con-
vulsion (4.1% each), status epilepticus and pneumonia aspiration
(1.5% each), and lobar pneumonia, sepsis, septic shock, urinary tract in-
fection, dehydration, sedation, somnolence, and aggression (1.1% each).Table 3
Cross-tabulation of numbers of concomitant AEDs at baseline and ﬁnal evaluation.
Number of concomitant
AEDs at baseline
Number of concomitant AEDs at ﬁnal evaluation
1 2 3 >3
1 19 4 1 0
2 17 73 12 2
3 4 32 33 9
>3 0 6 4 13
AEDs = antiepileptic drugs.3.4.2.3. Serious adverse events. Serious adverse events were reported
for 85 patients (31.8%) during clobazam exposure in the OV-1004.
Serious adverse events that occurred in more than 2% of patients
were pneumonia (9.4%), convulsion (8.2%), pneumonia aspiration
(3.7%), lobar pneumonia (2.2%), and urinary tract infection (2.2%).
Treatment-related serious adverse events were reported for 15 pa-
tients (5.6%), of which pneumonia (4 patients), convulsion (3 pa-
tients), and status epilepticus (2 patients) were the only serious
adverse events reported for >1 patient.
As of the interim data cutoff (July 1, 2010), 6 patients (2.2%) had
died during this open-label study. Fatal adverse events were pneumo-
nia (2 patients); epilepsy (1 patient); pneumonia, sepsis, and acute
respiratory distress syndrome (1 patient); and death of unknown
origin or etiology (2 patients). None was considered related to
clobazam treatment.
4. Discussion
This long-term study of clobazam (OV-1004) is the largest open-
label extension trial in patients with LGS published to date, and this
interim analysis provides long-term data on the safety, tolerability,
and efﬁcacy of clobazam in this population. Notable ﬁndings include
a high patient retention rate, stable dosages, and continued substan-
tial seizure improvements for patients treated ≥2 years.
The paucity of long-term trial data has been a challenge for formu-
lating LGS treatment guidelines. Only 2 other long-term extension tri-
als have been presented, a 1-year extension of a felbamate trial with
73 patients [10] and a 3-year extension of a ruﬁnamide trial with
124 patients [11]. The long-term data from OV-1004 should be valu-
able in helping physicians who treat patients with LGS determine
long-term treatment options.
The intractable, variable, and progressive nature of LGS makes it
one of the most challenging seizure disorders to diagnose and treat
[1,4]. In previous randomized trials, clobazam was found to be both
safe and efﬁcacious for treatment of seizures associated with LGS
[7,8]. Decreases in average weekly drop attacks and total seizures ob-
served in the previous trials have been sustained and have continued
to improve throughout the entire open-label trial to date. Responder
rates, as measured by percentage decreases in weekly rate of drop at-
tacks and total seizures, were also sustained through the ﬁrst 2 years
of this open-label extension trial, despite the fact that several con-
founding factors (e.g., other therapies, changes in disease course,
varying treatment lengths at time of interim analysis, changes in
clobazam dosage, and development of tolerance) may have affected
response rates over time.
Given the variety of seizure types associated with LGS, drugs with
a wide spectrum of efﬁcacy are needed to treat this syndrome [5]. Al-
though the goal of a broad-spectrum antiepileptic drug is to limit or at
least delay the need for polytherapy [5], it is likely, given the resistant
nature of LGS and its heterogeneity, that more than one AED will
693Y.-T. Ng et al. / Epilepsy & Behavior 25 (2012) 687–694eventually be needed for the vast majority of patients [1,4]. Given the
likely need for polytherapy for patients with LGS, the stability of the
clobazam dosage was carefully monitored in the OV-1004
open-label extension trial and was generally stable and remained
well less than 2 mg/kg maximum for most patients at the interim
cutoff. Development of tolerance can often be a problem with 1,4-
benzodiazepines [13]. Although we did not prospectively evaluate it
per se, development of tolerance did not appear to be a signiﬁcant fac-
tor, as suggested by the following: 1) No diminution of response rates
was observed during the ﬁrst 2 years of the open-label trial; 2) Mean
modal clobazam dosages did not increase with time; 3) Approximate-
ly 80% of patients had remained in long-term treatment; and 4) A trend
toward decreases in the numbers of concomitant epilepsy treatments
was observed for some patients. Persistence of clobazam's efﬁcacy
was observed previously [9,12].
Though efﬁcacy data from long-term trials are informative, they
should be interpreted with caution, as patients who discontinue be-
cause of a lack of efﬁcacy may enrich the pool of patients for whom
the drug is efﬁcacious. At the data cutoff date, b5% of patients dis-
continued the trial for lack of efﬁcacy, indicating this is not yet a
major factor in OV-1004. A common limitation of open-label exten-
sion studies is that patients who are the best responders tend to re-
main in the studies the longest, leading to responder bias. This bias
may have occurred in our study as well, and its potential contribution
to the results cannot be excluded. Further, OV-1004 study investiga-
tors were permitted to optimize treatment regimens for patients by
freely adding, removing, or adjusting dosages of concomitant AEDs
and employ other treatment options, such as VNS and ketogenic
diet. In addition, the natural course of LGS varies considerably, and
the disease may be less severe for older patients. Concomitant thera-
pies, responder bias, and the variable natural course of the disease are
potential confounders of the results presented here.
Unlike guidelines for most seizure disorders, complete seizure re-
mission is not considered a realistic treatment goal in the consensus
publication for LGS management, as it is rarely attained in patients
with LGS [1]. Instead, overall patient quality of life is considered
more important, and global evaluations by both the physician and
caregiver/patient in this trial indicate that the majority of patients im-
proved with clobazam treatment. The 80% retention rate in the ﬁrst
2 years of OV-1004 also indicates overall treatment satisfaction and
therapy compliance for most patients.
Since LGS is a syndrome that will require a lifetime of treatment
and, likely, polytherapy, it is particularly important that drugs used
in its management have a favorable long-term safety proﬁle. Some
of the approved treatments can have serious adverse effects, such as
aplastic anemia (felbamate) [14,15] and serious rash (lamotrigine)
[16]. Clobazam seems to be well-tolerated, given the safety proﬁle
noted in this 2-year analysis. Themost commonadverse events reported
with clobazam use, such as respiratory infections and falls, were to be
expected in a long-term trial in the LGS patient population. In addition,
upper respiratory tract infection and pneumonia events occurred pre-
dominantly in pediatric patients, which is quite common for trials in ep-
ilepsy with pediatric patients. The interim OV-1004 open-label
extension trial data indicate no new safety concerns when compared
with the results of short-term controlled trials.
The seemingly stable clobazam safety proﬁle and potential for
clinical beneﬁt over the ﬁrst 2 years of OV-1004, coupled with the de-
cades of global use in LGS and other seizure disorders, indicate that
clobazam is a viable long-term treatment option for this intractable
epilepsy syndrome.
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